Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.63 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | CHKA | P35790 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25888837 | 0.94 | ALDH1A1 (0.57) | MAPTGAAALDH1A1KDM4EPTK2B | |
| SCHEMBL24518338 | 0.92 | CHKA (0.62) | MAPTGAAALDH1A1KDM4EPTK2B | |
| SCHEMBL14345952 | 0.88 | AKR1C3 (0.57) | MAPTGAAALDH1A1KDM4EPTK2B | |
| SCHEMBL15268156 | 0.82 | ADRB1 (0.57) | MAPTALDH1A1KMT2ALMNANPC1 | |
| SCHEMBL23422581 | 0.82 | L3MBTL3 (0.53) | MAPTGAAALDH1A1KDM4EPTK2B | |
| SCHEMBL24596956 | 0.82 | L3MBTL3 (0.58) | MAPTGAAALDH1A1KDM4EPTK2B | |
| SCHEMBL15489560 | 0.79 | MAPT (0.65) | MAPTGAAALDH1A1KDM4EPTK2B | |
| SCHEMBL81814 | 0.79 | MAPT (0.65) | MAPTGAAALDH1A1KDM4EPTK2B | |
| SCHEMBL625677 | 0.78 | ALDH1A1 (0.54) | MAPTGAAALDH1A1KDM4EKMT2A | |
| SCHEMBL18815076 | 0.78 | LTA4H (0.52) | MAPTGAAALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620954-A1 | CDK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shandong Luye Pharmaceutical Co., Ltd. (CN) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024104455-A1 | CDK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 山东绿叶制药有限公司 | 2024-05-23 | — | — | WO | disclosed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-3755689-B1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-11584746-B2 | Inhibitors of EGFR and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584746-B2 | Inhibitors of EGFR and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2023011610-A1 | BENZODIOXANE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 南京红云生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| US-20220347299-A1 | FLUORESCENT SYSTEMS FOR BIOLOGICAL IMAGING AND USES THEREOF | LightOx Limited (GB) | 2022-11-03 | — | — | US | disclosed |
| US-20150166525-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R TECH UENO LTD (JP) | 2015-06-18 | — | — | US | disclosed |
| US-8999989-B2 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8999989-B2 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8999989-B2 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| EP-2300430-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-Tech Ueno, Ltd. (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20110059957-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2011-03-10 | — | — | US | disclosed |
| US-20110059957-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2011-03-10 | — | — | US | disclosed |
| US-20110059957-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2011-03-10 | — | — | US | disclosed |
| WO-2009145360-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2009-12-03 | — | — | WO | disclosed |
| US-5725838-A | Radiolabeled D4 receptor ligands | RESOLUTION PHARMACEUTICALS, INC. (CA) | 1998-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166525-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | VAPB, VAPA, BET1 | MAPT 1522/4885GAA 2070/4885ALDH1A1 141/4885 |
| US-11584746-B2 | Inhibitors of EGFR and methods of use thereof | EGFR, ERBB2, ERBB3 | MAPT 1297/4885GAA 1074/4885ALDH1A1 2938/4885 |
| US-20110059957-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | VAPB, VAPA, BET1 | MAPT 1522/4885GAA 2070/4885ALDH1A1 141/4885 |
| US-20220347299-A1 | FLUORESCENT SYSTEMS FOR BIOLOGICAL IMAGING AND USES THEREOF | SON, DNER, CASR | MAPT 1497/4885GAA 4720/4885ALDH1A1 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.